Thelansis

  Glioblastoma (GBM) is the most aggressive diffuse glioma of the astrocytic lineage. It is the most common malignant primary brain tumor making up 54% of all gliomas and 16% of all primary brain tumors. GBM treatment is complex, initially consisting of maximally safe surgical resection followed by radiation therapy (RT) and concurrent Temozolomide (TMZ) chemotherapy. Glioblastoma has an incidence of 2 to 3.4 per 1,00,000 population in the US and Europe. Thelansis’s “Glioblastoma (GBM) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glioblastoma (GBM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Gli...